17,956 Shares in Mesoblast Limited (NASDAQ:MESO) Acquired by Creative Planning

Creative Planning bought a new position in shares of Mesoblast Limited (NASDAQ:MESO) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 17,956 shares of the company’s stock, valued at approximately $147,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MESO. GAMMA Investing LLC grew its holdings in Mesoblast by 50.1% in the 2nd quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock valued at $34,000 after buying an additional 1,663 shares during the last quarter. Perkins Coie Trust Co acquired a new stake in shares of Mesoblast in the second quarter worth $68,000. Chapin Davis Inc. increased its position in Mesoblast by 50.0% during the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock worth $102,000 after acquiring an additional 5,000 shares during the period. Pine Valley Investments Ltd Liability Co acquired a new position in Mesoblast during the 2nd quarter valued at $80,000. Finally, Rathbones Group PLC bought a new stake in Mesoblast in the 2nd quarter valued at $95,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Stock Performance

MESO opened at $9.95 on Wednesday. Mesoblast Limited has a 1-year low of $1.61 and a 1-year high of $11.05. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The firm has a 50-day moving average price of $8.26 and a two-hundred day moving average price of $7.51.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Piper Sandler upgraded shares of Mesoblast from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $4.00 to $11.00 in a report on Tuesday, July 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. StockNews.com downgraded Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Jefferies Financial Group upgraded Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. Finally, Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Mesoblast has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.